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Abstract
Background: Hypertension is a major contributor to cerebrovascular and heart disease. Of the patients who
are medically managed but not meeting blood pressure goals, there is a subset of patients who have resistant
hypertension, a condition requiring more aggressive technology and treatment to assist in the reduction of
their blood pressure. The sympathetic innervation of the kidneys plays an intricate role in these patients and is
becoming the target for future treatment alternatives. Will the use of renal radiofrequency ablation (RFA) be
an effective therapeutic option for patients with resistant hypertension?
Methods: An exhaustive search of available and applicable literature was conducted using Medline-OVID,
Evidence Based Medicine Reviews Multifile, CINAHL, and Google Scholar by using the key words: resistant
hypertension, kidney, renal denervation, sympathectomy and radiofrequency ablation. Relevant articles were
assessed for quality using GRADE and are found in the Table section of this paper. A search on the NIH
clinical trials website revealed few completed trials, but showed multiple trials that are in process or recruiting
for further investigation of the efficacy of renal radiofrequency ablation for the treatment of resistant
hypertension.
Results: Two studies met inclusion criteria and are discussed in this systematic review. A randomized
controlled study with 106 participants demonstrated a statistically significant reduction in blood pressure
following renal denervation. A proof-of-principle cohort study with 50 participants demonstrated a
statistically significant and sustained reduction in blood pressure for those who received renal radiofrequency
ablation therapy.
Conclusion: Renal radiofrequency ablation has been shown to reduce blood pressure in patients with
resistant hypertension with no evidence of serious complications. RFA has also been shown to be a cost
effective therapeutic alternative when comparing the long-term cost of treating hypertension to the upfront
cost of the procedure. Due to the existing low quality of available studies, more thorough research is needed to
confirm long-term efficacy of RFA as a treatment option for patients with resistant hypertension.
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Abstract   
Background:  Hypertension is a major contributor to cerebrovascular and heart disease.  
Of the patients who are medically managed but not meeting blood pressure goals, there is 
a subset of patients who have resistant hypertension, a condition requiring more 
aggressive technology and treatment to assist in the reduction of their blood pressure.  
The sympathetic innervation of the kidneys plays an intricate role in these patients and is 
becoming the target for future treatment alternatives.  Will the use of renal 
radiofrequency ablation (RFA) be an effective therapeutic option for patients with 
resistant hypertension? 
 
Methods:  An exhaustive search of available and applicable literature was conducted 
using Medline-OVID, Evidence Based Medicine Reviews Multifile, CINAHL, and 
Google Scholar by using the key words: resistant hypertension, kidney, renal denervation, 
sympathectomy and radiofrequency ablation.  Relevant articles were assessed for quality 
using GRADE and are found in the Table section of this paper.  A search on the NIH 
clinical trials website revealed few completed trials, but showed multiple trials that are in 
process or recruiting for further investigation of the efficacy of renal radiofrequency 
ablation for the treatment of resistant hypertension. 
 
Results:  Two studies met inclusion criteria and are discussed in this systematic review.  
A randomized controlled study with 106 participants demonstrated a statistically 
significant reduction in blood pressure following renal denervation.  A proof-of-principle 
cohort study with 50 participants demonstrated a statistically significant and sustained 
reduction in blood pressure for those who received renal radiofrequency ablation therapy.  
 
Conclusion:  Renal radiofrequency ablation has been shown to reduce blood pressure in 
patients with resistant hypertension with no evidence of serious complications.  RFA has 
also been shown to be a cost effective therapeutic alternative when comparing the long-
term cost of treating hypertension to the upfront cost of the procedure.  Due to the 
existing low quality of available studies, more thorough research is needed to confirm 
long-term efficacy of RFA as a treatment option for patients with resistant hypertension. 
 
Keywords: resistant hypertension, kidney, renal denervation, sympathectomy and 
radiofrequency ablation   
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The Efficacy of Renal Radiofrequency Ablation for the Treatment of Resistant 
Hypertension 
BACKGROUND 
  Worldwide, more than a quarter of the adult population totaling nearly one billion, 
had hypertension in 2000.  This proportion of individuals is projected to increase to 1.56 
billion by 2025. 1  Furthermore, according to a 2012 World Health Organization report, 
one in three adults worldwide has elevated blood pressure, a medical condition that has 
been found to cause approximately half of all deaths from stroke and heart disease. 2  
With such a large percentage of the population being faced with hypertension as a 
medical problem, the ultimate goal of antihypertensive therapy is to reduce overall 
cardiovascular and renal morbidity and mortality.  The treatment goal for individuals 
with hypertension and no associated high-risk conditions such as heart failure, post 
myocardial infarction, diabetes, chronic kidney disease, or recurrent stroke, is <140/90 
mmHg. 3 
There is a subset of hypertensive patients, who despite many efforts, are 
considered to be uncontrolled or resistant to medical management.  Resistant 
hypertension has been defined as the failure to achieve blood pressure (BP) goals in 
patients who are adhering to full doses of an appropriate three-drug regimen that must 
include a diuretic. 3  It is becoming a more common medical dilemma that many 
clinicians are challenged with and are being forced to address. As our population 
continues to age and as obesity becomes more widespread, resistant hypertension is 
expected to become even more common. 4  “The prevalence and prognosis of resistant 
hypertension have not yet been examined by proper population studies, but data from 
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several sources suggest that this entity is not uncommon and is associated with an 
elevated risk of hypertensive complications”.  With this elevated risk of complications, 
resistant hypertension is suggested to have an unfavorable prognosis. 5 
When considering this public health concern, the necessity of maximizing the 
effectiveness of existing therapeutic approaches as well as expanding available treatment 
options for both patients and clinicians are priorities.  Ideally, development of additional 
therapeutic alternatives would not only assist in improving blood pressure control, but it 
would also beneficially impact comorbid conditions commonly associated with 
hypertension.  The prospective of new therapeutic alternatives, such as renal 
radiofrequency ablation, has the potential to improve the management of resistant 
hypertension by selectively targeting organs or nerves without competing with, or 
opposing the systemic effects of medical management. 6  The consideration and 
implementation of such therapeutic alternatives may be an increasingly important adjunct 
therapy for patients with resistant hypertension who fail to be controlled with medical 
management alone. 7 
The role of the sympathetic nervous system in hypertension has been thoroughly 
studied. 5-10  In general, the various effects of increased renal sympathetic nerve activity 
include, but are not limited to, renal vasoconstriction, decreased glomerular filtration rate 
(GFR) and renal blood flow, increased renal vascular resistance, increased renal sodium 
retention and increased release of renin and norepinephrine.  In considering these effects, 
the renal sympathetic nerves likely serve as a critical link between the sympathetic 
nervous system and the kidney when looking at hypertension. 8  With this knowledge, 
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clinicians can take a closer look at finding a therapy that targets the kidneys and their 
intricate causal relationship with hypertension. 
Sympathectomy is a type of procedure that has been around for many years.  
Specific for the treatment of hypertension, one of the first attempts to modify the course 
of hypertensive disease by sympathectomy was done in 1924.  In the process of 
preforming these early attempts, two known effects of sympathectomy were discovered 
and mentioned.  The first was the overall modification of blood pressure levels, and the 
second was the modification of the reflex regulation of blood pressure, or baroreflex, 
resulting from the inactivation of certain components of the vasoconstrictor mechanism. 9  
It is this reason for which RFA of the renal artery is becoming a targeted therapy option 
for patients with resistant hypertension. 
Catheter-based renal artery sympathetic denervation is considered to be a 
minimally invasive procedure where the procedure universally begins by gaining 
percutaneous access through the femoral artery and then a guide catheter is introduced, 
and subsequently engaged into the renal artery.  At this point, a specially designed 
catheter is advanced, placed at the distal section of the renal artery and low-power 
radiofrequency energy is delivered to the endothelial layer. 6,7  Delivering radiofrequency 
energy causes transmural lesions and consequently damages the sympathetic fibers 
traveling in the adventitia of the arterial wall. 7,10  Overall, RFA therapy is directed at 
disrupting the sympathetic innervation to the kidneys.  Is the use of renal radiofrequency 
ablation an effective therapeutic option for patients with resistant hypertension? 
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METHODS 
An exhaustive search of available and applicable literature was conducted using 
Medline-OVID, Evidence Based Medicine Reviews Multifile, CINAHL, and Google 
Scholar by using the key words: resistant hypertension, kidney, renal denervation, 
sympathectomy and radiofrequency ablation.  The search was narrowed to include only 
English language articles as well as only randomized control trials or observational 
studies in order to evaluate literature with the highest level of evidence.  Multiple studies 
referencing RFA were found, but many were focused on various other endpoints or were 
case series type studies, all of which were subsequently excluded.  The bibliographies of 
the articles were examined for any additional relevant information. Articles specific to 
renal denervation as a therapy for resistant hypertension with blood pressure reduction as 
the primary endpoint were included for further analysis and support documentation.  
Relevant articles were assessed for quality by using the Grading of Recommendations, 
Assessment, Development and Evaluation (GRADE). 11  A search in the National 
Institute of Health (NIH) clinical trials website revealed few completed trials; however, it 
showed multiple trials that are in the process of recruiting patients for further 
investigation of the efficacy of renal RF ablation for the treatment of resistant 
hypertension. 
RESULTS 
The initial search yielded 109 articles for review.  After screening these articles 
for the primary endpoint of blood pressure reduction, two articles met specific inclusion 
criteria. This includes one randomized control trial (RCT) 12 and one observational cohort 
study (Table I). 13 
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Symplicity HTN-2 Trial  
  This multi-center, prospective, randomized trial 12 examined the effectiveness and 
safety of catheter-based renal denervation for reduction of blood pressure in patients with 
treatment-resistant hypertension.  The trial screened 190 patients, of which 84 were 
excluded by not meeting blood pressure inclusion criteria, by having an anatomical renal 
abnormality, or by declining to participate.  In total, 106 patients were designated to 
either the treatment or control group.  The primary endpoint measured in this study was 
the average, office-based change in systolic blood pressure from baseline to 6 months.   
Secondary endpoints included acute procedural safety and chronic procedural safety, 
looking specifically at reduction in estimated glomerular filtration rate (eGFR) or intimal 
damage to the renal artery causing a new area of stenosis.  There was also a composite 
cardiovascular endpoint (myocardial infarction, sudden cardiac death, new-onset heart 
failure, death from progressive heart failure, stroke, aortic or lower limb revascularization 
procedure, lower limb amputation, death from aortic or peripheral arterial disease, 
dialysis, death because of renal failure, hospital admission for hypertensive emergency 
unrelated to non-adherence or non-persistence with drugs, and hospital admission for 
atrial fibrillation). 12 
  Eligibility criteria included patients 18-85 years of age, systolic blood pressure 
(SBP) of 160 mmHg or more, SBP of 150 mmHg or more in patients with type 2 
diabetes, persistent hypertension even when compliant on three or more antihypertensive 
medications.  Screening was done at 24 centers in Europe, Australia, and New Zealand 
where patients underwent renal artery anatomy evaluation, baseline lab evaluation, as 
well as baseline blood pressure monitoring before being assigned to their prospective 
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groups.  Patients were then randomly assigned in a 1:1 ratio to either the renal 
denervation group or control by sealed envelopes.  There were 52 patients allocated to the 
renal denervation group and 54 allocated to the control group.  The participants assigned 
to both the intervention and control group were balanced in regards to baseline clinical 
characteristics.  For patients randomly assigned to undergo renal denervation, the femoral 
artery was accessed and the Symplicity Catheter System (Ardian, USA) was advanced 
into the renal artery whereby multiple, low-power radiofrequency treatments were 
applied along the length of both renal arteries. 12 
RFA therapy significantly reduced the primary endpoint of office-based systolic 
blood pressure (Table II).  More specifically, results after 6 months illustrated that with a 
blood pressure average of 178/96 mmHg, measurements in the renal denervation group 
were reduced by 32/12 mm (p<0.0001 for systolic and diastolic blood pressure).  For the 
control group, with a blood pressure average of 178/97 mmHg, measurements changed 
by 1/0 mm Hg, p=0.77 for systolic blood pressure, p=0.83 for diastolic blood pressure.  
Three patients from each group were lost to follow-up. 12 
 All other endpoint results are based on 6-month follow-up and are listed below.  
Results in regards to the secondary endpoint of acute procedural safety revealed no 
serious complications related to the device or procedure.  There were several minor 
periprocedural incidents noted including one femoral artery pseudoaneurysm requiring 
manual pressure only, one post-procedure drop in blood pressure requiring change in 
medication, one urinary tract infection, one extended hospital stay due to parasthesia, and 
one evaluation of back pain with resolution.  Chronic procedural safety illustrated that 
eGFR remained unchanged and no new lesions of the renal artery were attributed to the 
  - 13 -  
procedure itself.  The composite cardiovascular endpoints identified five hospital 
admissions for hypertensive emergency that were unrelated to non-adherence to drug 
therapy (three of these patients had renal denervation and two were controls); no other 
composite cardiovascular events occurred. 12 
The Cohort Study 
This proof-of-principle cohort study 13examined the safety and blood pressure 
reduction effectiveness when using renal sympathetic denervation in patients with 
resistant hypertension.  The trial enrolled a total of 50 participants, of which 5 were 
excluded for anatomical renal artery abnormalities.  In total, 45 patients were treated with 
renal denervation and the remaining 5 patients were followed for comparison.  The 
primary endpoints in this study were safety and blood-pressure lowering effectiveness of 
the procedure.  Secondary endpoints of this study included the effects of the procedure on 
renal noradrenaline spillover and renal function. 13  
 Eligibility criteria included patients at least 18 years old, non-pregnant, no known 
secondary cause of hypertension, GFR of 45 mL/min/1.73m², an office-based SBP of 160 
mm Hg or more despite being treated with at least three antihypertensive drugs (including 
one diuretic), or confirmed intolerance to current medication regimens.  Patients were 
recruited from 5 centers in Australia and Europe.  Initial screening included anatomical 
evaluation as mentioned above, physical exam, baseline vital signs, basic lab work, and a 
pregnancy test where applicable.  In 12 patients, 24-hour ambulatory blood pressures 
were monitored pre- and post-procedure.  Patients in the treatment group were initially 
staged to evaluate safety where the first ten patients underwent procedures with single 
renal artery treatment, followed by angiogram and treatment of the contralateral artery 1 
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month later.  Eight patients had simultaneous bilateral treatments with renal angiogram 1 
month after treatment, and the remaining 27 patients had simultaneous bilateral renal 
artery treatment without follow-up angiogram.  Treatment included femoral access, guide 
catheter engagement into the renal artery with the Symplicity catheter, and then a series 
of discrete radiofrequency ablations were applied within each renal artery. 13   
 The participants of this study were all balanced in regards to baseline clinical 
characteristics.  Of the 45 patients that were treated with renal denervation, 26 were 
available for follow-up at 6 months and only 9 patients were available at 12 months.  Of 
the 5 patients who were not treated, all were available for follow-up at 6 months and only 
2 were available at 12 months. 13 
 This study revealed that RF ablation therapy resulted in a significant and 
continued blood-pressure reduction (Table II).  More specifically, results for office-based 
blood pressure revealed that with an average baseline blood pressure of 177/101 mm Hg, 
the patients who received renal denervation seen at 1 month, 3 months, 6 months, 9 
months, and 12 months had mean reductions of -14/-10, -21/-10, -22/-11, -24/-11, and -
27/-17, respectively (p<0.001 with exception at 12 months, p=0.05).  The results also 
demonstrated that 6 of the 45 patients (13%) had systolic blood-pressure reductions of 
less than 10 mm Hg (no response).  The 5 patients who were only followed for data 
purposes showed an increase in mean blood pressure overall.  In regards to the other 
primary endpoint of safety, in 45 patients, one patient had a renal artery dissection due to 
catheter placement before therapy was initiated and another patient developed a 
pseudoaneurysm at the femoral artery access site without further complication. 13 
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 Secondary endpoints included the evaluation of renal noradrenaline spillover and 
renal function, which are as follows.  Ten patients were evaluated and assessed for the 
effectiveness of the procedure in achieving efferent renal denervation after procedure 
changes specific to renal noradrenaline spillover.  The mean reduction in these patients 
was 47% (95% CI 28–65%).   These same patients had a mean 6-month office blood-
pressure reduction of 22/12 mm Hg, which was similar to the overall treatment group.  In 
follow-up, the renal function of 25 patients was assessed by comparing baseline GFR 
values to post-procedure values.  Patients with low baseline GFR seemed to have a 
greater but not significant (p=0.30) increase in GFR, 13 in other words, there was no 
significant decrease in renal function. 
DISCUSSION 
 
Catheter-based renal radiofrequency ablation is proven to be an effective 
treatment option for resistant hypertension as evident by the Symplicity HTN-2 trial 12 
and the cohort study. 13  In addition, RFA reduced cardiovascular mortality by 30% and 
all-cause mortality by 15% over a 10 year period. 14  The One-Year Results of the 
Symplicity HTN-2 RCT 15, posted December 2012, reports that follow-up of the initial 
renal denervation cohort of patients who showed a mean reduction of 32 mmHg at 6 
months after RFA is sustained with a reduction of 28 mmHg at 12-month follow-up. 15  
Currently, there is additional work being done to further support this existing data.  The 
Symplicity HTN-3 trial16 is an ongoing prospective, single-blind, randomized, controlled 
study investigating the safety and effectiveness of renal denervation in subjects with 
uncontrolled hypertension. 16  This trial16 is investigating 530 patients with a primary 
endpoint of change in office-based systolic blood pressure from baseline to 6 months.  In 
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addition to the previously mentioned benefits of RFA as a therapeutic option, patient 
important outcomes have also been considered.  The overall quality of life for patients 
after RFA has shown a noticeable reduction in subjective health-related quality of life 
issues predominantly related to mental health. 17 
RFA is currently being used as therapy option for resistant hypertension in 
Europe, Australia, and New Zealand as illustrated in the previous studies.  In the United 
States, RFA is not yet approved, however, the results from the Symplicity HTN-3 trial 
will be submitted to the US Food and Drug Administration for evaluation and approval of 
catheter-based renal denervation as a treatment option for resistant hypertension. 16  In 
addition to official studies that are being conducted, recent news reports are focusing on 
RFA as a future therapy.  The latest from Medical News Today on February 15, 2013 
reported that a “novel drug-free treatment consisting of blasting nerves in the kidneys 
with radio waves is helping to decrease high blood pressure in patients”. 18  With the 
existing demonstrated efficacy and current efforts for more solid evidence, RFA should 
be considered as a potential forefront for future treatment of resistant hypertension.   
There has been some cost analysis in regards to RFA since its inception.  The 
statistical model estimated the renal radiofrequency ablation procedure cost to be $12 500 
and that hypertension management costs an average of $868 annually.  This directly 
reflects the fact that the cost of the procedure is incurred up front while the subsequent 
savings is acquired over a lifetime. 19  This information further supports the potential use 
of RFA as a therapeutic option. 
However, there are several limitations that exist in both the RCT 12 and cohort 
study  13 discussed previously.  In regards to the RCT, 12 the methodology here is slightly 
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limited in regards to blinding.  Performance bias automatically exists in this scenario due 
to the fact that even though data-analyzers were masked, it is impossible to mask the 
participant.  With this, there is potential concern for the Hawthorne effect whereby 
patients are influenced by their situation, ie, treatment or control.  The study addresses 
this issue and states that controls showed no Hawthorne effect. 12  In addition to 
performance bias, there is also risk of publication bias as the study mentions funding 
from the catheter company. 
In regards to the cohort study, 13 limitations include first and foremost, the fact 
that this is a small proof-of-concept study13 with no official control group.  With this, the 
Hawthorne effect is a concern again, whereby patients have the potential to be influenced 
by their particular therapy as previously mentioned.  There is a risk of publication bias as 
the study addresses that fact that the sponsor of the study participated in the design of the 
study, analysis of data, and review of the final manuscript.  The different types of 
monitoring and follow-up mentioned in this particular study were proven to not be very 
consistent.  The study mentions several issues below where only a few patients were 
monitored and followed for each: ambulatory blood pressure monitoring, assessment for 
renal noradrenaline spillover, follow-up renal angiograms, and follow-up renal magnetic 
resolution angiography.13  
CONCLUSION 
Both the RCT and cohort study included in this systematic review have provided 
evidence to support the use of renal radiofrequency ablation as an effective therapy 
option for blood pressure reduction in patients with resistant hypertension.  The overall 
combined quality of these studies is low based on the GRADE criteria.  However, 
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research is moving forward with a larger, blinded, randomized control trial to further 
validate RFA as a good, safe and long-term alternative when treating resistant 
hypertension.  Renal denervation has also been demonstrated to be a cost effective option 
for the reduction of blood pressure in patients with resistant hypertension.  In terms of 
clinical practice, the use of renal RFA is an interesting and potentially valuable option in 
the future once higher quality studies and long-term results have been addressed. 
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 Table I.  Characteristics of Reviewed Studies 
aNo blinding in either study 12,13 
bSmall sample size 
 
 
 
 
Table II. Summary of Findings 
 Office-Based SBP/DBP mm Hg Mean Reduction  
Symplicity HTN-  
Trial 12  
1 month 3 months 6 months 9 months 12 months 
RFA (n=52) -20/-7 -24/-8 -32/-12 __ __ 
 
Control (n=54) 0/0 -4/-2 1/0 __ 
 
__ 
The Cohort 
Study 13  
1 month 3 months 6 months 9 months 12 months 
RFA (n=45) -14/-10 -21/-10 -22/-11 -24/-11 
 
-27/-17 
No treatment 
(n=5) 
+3/-2 +2/+3 +14/+9 
 
+26/+17 __ 
 
 
 
 
Quality Assessment 
Study Detail Downgrade Criteria Upgrade Criteria 
Quality 
Participants Design Limitations Indirectness Imprecision Inconsistency Publication bias likely 
Large 
effective 
Magnitude 
Confounding 
Factors 
reducing 
effect 
Dose-
response 
gradient 
Renal Sympathetic Denervation in Patients with Treatment-resistant Hypertension (The Symplicity HTN-2 Trial): A Randomized Controlled 
Trial 12 
106 RCT Serious  limitationsa 
No serious 
indirectness 
No serious  
imprecision 
No serious 
inconsistencies Yes - -
 - Moderate 
Catheter-based Renal Sympathetic Denervation for Resistant Hypertension: A Multi-center Safety and Proof-of-principle Cohort Study 13 
45 Obs Serious  limitationsa 
No serious 
indirectness 
Serious  
imprecisionb 
No serious 
inconsistencies Yes - - - Very Low 
